Harrow, Inc. Stock Issued During Period, Value, Restricted Stock Award, Gross
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Harrow, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2026-06-30 was $0.00.
- Harrow, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2025-06-30 was $0.00.
- Harrow, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2013 was $143.55K, a 2.95% increase from fiscal 2012.
- Harrow, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2012 was $139.44K.
- Harrow, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2010 was $12.08K.
- Harrow, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2008 was $0.00.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Gross 3 month | Stock Issued During Period, Value, Restricted Stock Award, Gross 12 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-10 | |
| 2013-12-31 | $143.55K 10-K · filed 2014-03-28 | |
| 2012-12-31 | $139.44K 10-K · filed 2014-03-28 | |
| 2010-12-31 | $12.08K 10-K · filed 2013-03-18 | |
| 2008-12-31 | $0.00 10-K · filed 2013-03-18 | |
| 2007-12-31 | $0.00 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |